Human primary immunodeficiency caused by expression of a kinase-dead p110δ mutant

Sarah Beaussant Cohen; Wayne Bainter; Jared L. Johnson; Ting Yu Lin; Jenny C.Y. Wong; Jacqueline G. Wallace; Jennifer Jones; Sonia Qureshi; Fatima Mir; Farah Qamar; Lewis C. Cantley; Raif S. Geha; Janet Chou

doi:10.1016/j.jaci.2018.10.005

Human primary immunodeficiency caused by expression of a kinase-dead p110δ mutant

Sarah Beaussant Cohen, Wayne Bainter, Jared L. Johnson, Ting Yu Lin, Jenny C.Y. Wong, Jacqueline G. Wallace, Jennifer Jones, Sonia Qureshi, Fatima Mir, Farah Qamar, Lewis C. Cantley, Raif S. Geha, Janet Chou

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Original language	English
Pages (from-to)	797-799.e2
Journal	Journal of Allergy and Clinical Immunology
Volume	143
Issue number	2
DOIs	https://doi.org/10.1016/j.jaci.2018.10.005
Publication status	Published - Feb 2019

Access to Document

10.1016/j.jaci.2018.10.005

Cite this

@article{8e9927ef242b461b8f17ed4c49462099,

title = "Human primary immunodeficiency caused by expression of a kinase-dead p110δ mutant",

author = "Cohen, {Sarah Beaussant} and Wayne Bainter and Johnson, {Jared L.} and Lin, {Ting Yu} and Wong, {Jenny C.Y.} and Wallace, {Jacqueline G.} and Jennifer Jones and Sonia Qureshi and Fatima Mir and Farah Qamar and Cantley, {Lewis C.} and Geha, {Raif S.} and Janet Chou",

note = "Funding Information: This study was supported by grant number 5T32AI007512-33 (S.B.C.), grant number NCI R35 CA197588 (L.C.C.), grant number 5K08AI116979-04 (J.C.), grant number 1R01AI139633-01 (R.S.G.), and the Perkin Fund (R.S.G.). Funding Information: This study was supported by grant number 5T32AI007512-33 (S.B.C.), grant number NCI R35 CA197588 (L.C.C.), grant number 5K08AI116979-04 (J.C.), grant number 1R01AI139633-01 (R.S.G.), and the Perkin Fund (R.S.G.).Disclosure of potential conflict of interest: L. C. Cantley is a founder and member of the SAB of Agios Pharmaceuticals and of Petra Pharmaceuticals. L. C. Cantley's laboratory receives financial support from Petra Pharmaceuticals. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Disclosure of potential conflict of interest: L. C. Cantley is a founder and member of the SAB of Agios Pharmaceuticals and of Petra Pharmaceuticals. L. C. Cantley's laboratory receives financial support from Petra Pharmaceuticals . The rest of the authors declare that they have no relevant conflicts of interest. ",

year = "2019",

month = feb,

doi = "10.1016/j.jaci.2018.10.005",

language = "English",

volume = "143",

pages = "797--799.e2",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - Human primary immunodeficiency caused by expression of a kinase-dead p110δ mutant

AU - Cohen, Sarah Beaussant

AU - Bainter, Wayne

AU - Johnson, Jared L.

AU - Lin, Ting Yu

AU - Wong, Jenny C.Y.

AU - Wallace, Jacqueline G.

AU - Jones, Jennifer

AU - Qureshi, Sonia

AU - Mir, Fatima

AU - Qamar, Farah

AU - Cantley, Lewis C.

AU - Geha, Raif S.

AU - Chou, Janet

N1 - Funding Information: This study was supported by grant number 5T32AI007512-33 (S.B.C.), grant number NCI R35 CA197588 (L.C.C.), grant number 5K08AI116979-04 (J.C.), grant number 1R01AI139633-01 (R.S.G.), and the Perkin Fund (R.S.G.). Funding Information: This study was supported by grant number 5T32AI007512-33 (S.B.C.), grant number NCI R35 CA197588 (L.C.C.), grant number 5K08AI116979-04 (J.C.), grant number 1R01AI139633-01 (R.S.G.), and the Perkin Fund (R.S.G.).Disclosure of potential conflict of interest: L. C. Cantley is a founder and member of the SAB of Agios Pharmaceuticals and of Petra Pharmaceuticals. L. C. Cantley's laboratory receives financial support from Petra Pharmaceuticals. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Disclosure of potential conflict of interest: L. C. Cantley is a founder and member of the SAB of Agios Pharmaceuticals and of Petra Pharmaceuticals. L. C. Cantley's laboratory receives financial support from Petra Pharmaceuticals . The rest of the authors declare that they have no relevant conflicts of interest.

PY - 2019/2

Y1 - 2019/2

UR - http://www.scopus.com/inward/record.url?scp=85057148014&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2018.10.005

DO - 10.1016/j.jaci.2018.10.005

M3 - Article

C2 - 30336224

AN - SCOPUS:85057148014

SN - 0091-6749

VL - 143

SP - 797-799.e2

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 2

ER -

Human primary immunodeficiency caused by expression of a kinase-dead p110δ mutant

Access to Document

Other files and links

Cite this